AAM: Exclusionary Biologics Contracts Will Hurt Emerging Biosimilars Market

Drug Industry Daily
A A
The Association for Accessible Medicines’ Biosimilars Council submitted an amicus brief supporting Pfizer in its antitrust lawsuit against Johnson & Johnson, arguing the company’s practices will keep biologics prices high and limit competition from biosimilars.

To View This Article:

Login

Subscribe To Drug Industry Daily